ebolaviru
marburgviru
marv
cuevaviru
genera
filovirida
famili
envelop
virus
nonseg
rna
caus
agent
sever
viral
hemorrhag
fever
vhf
classifi
biosafeti
pathogen
categori
agent
term
bioterror
taxonomi
filovirida
famili
kept
chang
time
sever
viru
name
abbrevi
creat
current
five
ebola
speci
earlier
consid
strain
subtyp
one
speci
recogn
name
zair
ebolaviru
ebov
sudan
ebolaviru
sudv
forest
ebolaviru
tafv
reston
ebolaviru
restv
bundibugyo
ebolaviru
bdbv
especi
ebov
sudv
respons
seriou
outbreak
ebola
hemorrhag
fever
ehf
ebola
viru
diseas
evd
among
human
nonhuman
primat
region
africa
ebov
virul
ebola
viru
fatal
rate
rang
evd
first
identifi
sudan
south
sudan
zair
democrat
republ
congo
outbreak
report
world
health
organ
sinc
transmiss
anim
human
believ
involv
direct
contact
infect
wild
anim
fruit
bat
consid
like
natur
reservoir
ebola
viru
recent
outbreak
west
start
march
repres
biggest
ebola
outbreak
far
consid
first
ebola
epidem
world
ever
brought
substanti
attent
scientif
commun
public
confirm
probabl
suspect
case
evd
report
six
african
countri
main
incid
guinea
liberia
sierra
leon
sever
isol
case
also
countri
spain
unit
state
report
case
fatal
rate
across
countri
estim
least
vhf
caus
filovirus
usual
character
nonspecif
symptom
includ
high
fever
sever
headach
myalgia
prostrat
follow
gastrointestin
symptom
diarrhea
nausea
vomit
sign
bleed
petechia
rash
dri
cough
chest
pain
behavior
disord
seizur
result
multiorgan
failur
ultim
death
due
multiorgan
failur
syndrom
resembl
septic
shock
typic
occur
within
day
develop
clinic
commonli
appli
standard
support
care
base
replac
bodi
fluid
patient
lose
infect
treatment
opportunist
infect
current
approv
drug
treat
ehf
although
sever
candid
develop
approv
treatment
variou
rna
viru
show
realli
potent
case
filoviru
diseas
hand
potenti
antivir
agent
pipelin
filoviru
experiment
drug
actual
repres
promis
option
prevent
treatment
evd
develop
ebov
vaccin
highli
desir
especi
protect
group
eg
medic
person
famili
member
patient
vaccin
complet
prevent
singl
case
even
new
ebov
outbreak
remot
area
west
africa
use
vaccin
furthermor
accompani
less
seriou
advers
effect
even
clear
effici
would
area
endem
variou
seriou
human
diseas
eg
malaria
moreov
local
commun
may
strongli
disagre
vaccin
develop
use
human
monoclon
antibodi
eg
zmapp
also
signific
limit
includ
stabil
difficulti
transport
problemat
product
reason
usag
antivir
invalu
approach
treatment
prevent
viral
infect
gener
develop
potent
agent
clearli
high
prioriti
ebov
genom
contain
seven
gene
np
vp
viral
protein
gp
l
encod
correspond
vp
filoviru
replic
complex
consist
genom
rna
molecul
four
protein
np
nucleoprotein
transcript
activ
polymeras
cofactor
l
rna
polymeras
matrix
protein
connect
glycoprotein
gp
actual
segment
central
number
step
filoviru
replic
cycl
theoret
target
inhibitor
name
attach
virion
receptor
fusion
viral
envelop
cellular
membran
replicationtranscript
process
assemblymatur
new
viral
particl
work
summar
discoveri
identif
number
small
molecul
import
viru
properti
promis
treatment
base
antisens
technolog
rna
interfer
rnai
also
briefli
mention
monoclon
antibodi
eg
zmapp
ebola
viru
develop
address
review
found
elsewher
group
compound
repres
structur
modifi
nucleosid
nucleotid
variou
mode
antivir
action
acycl
nucleosid
phosphon
compound
metabol
nucleotid
analogu
cell
also
includ
among
nucleosid
analogu
ribavirin
virazol
fig
antivir
drug
receiv
lot
ribavirin
report
activ
hemorrhag
fever
virus
eg
rift
valley
fever
viru
hemorrhag
fever
viru
vitro
vivo
effect
ebola
marburg
later
number
structur
adenosin
analogu
exampl
fig
fig
discov
inhibit
replic
ebov
vitro
block
sah
sah
hydrolas
key
enzym
methyl
reaction
depend
sam
methyl
donor
key
role
methyl
guanin
viral
messeng
rna
regul
cap
process
sinc
discoveri
sah
hydrolas
valuabl
pharmacolog
target
antivir
larg
varieti
adenosin
ado
analogu
potenti
sah
hydrolas
inhibitor
inhibitor
block
cleavag
sah
homocystein
hci
adenosin
metabol
amp
adenin
inosin
consequ
sah
hydrolas
inhibit
sah
accumul
cell
lead
inhibit
methyl
process
includ
requir
matur
ie
viral
mrna
consequ
matur
viral
mrna
suppress
product
progeni
viru
particl
fig
first
compound
demonstr
cure
mice
otherwis
lethal
ebov
bray
et
show
fig
singl
inocul
mgkg
given
first
second
day
viru
infect
also
afford
signific
protect
mice
lethal
infect
ebov
without
caus
acut
toxic
later
discov
protect
effect
might
result
massiv
increas
product
uninfect
mice
sah
hydrolas
inhibitor
receiv
limit
clinic
evalu
test
potenti
antifiloviru
properti
exert
antivir
activ
repres
attract
antivir
ye
report
enantiom
eg
fig
compound
potent
varieti
import
virus
includ
ebov
submicromolar
valu
eg
enantiom
fig
author
also
specul
sah
hydrolas
inhibit
site
action
enantiom
studi
need
fulli
understand
antivir
potenti
carbocycl
rigid
amphipath
fusion
inhibitor
rafi
exampl
compound
fig
uridin
nucleosid
analogu
bear
bulki
hydrophob
group
posit
rafi
repres
anoth
group
synthet
compound
inhibit
infect
sever
unrel
envelop
virus
includ
hcv
submicromolar
rang
cytotox
cytostat
effect
select
index
shown
rafi
inhibit
virion
fusion
result
shape
amphipath
rafi
evalu
emerg
virus
ebov
marv
anoth
promis
ebov
therapi
repres
compound
fig
report
novel
antivir
agent
adenin
analogu
immucillin
power
inhibitor
purin
nucleosid
phosphorylas
potenti
treatment
human
leukemia
lymphoma
exhibit
activ
numer
virus
includ
flavivirus
shown
inhibit
infect
distinct
filovirus
human
cell
postexposur
intramuscular
administr
protect
rodent
ebov
marv
viral
moreov
complet
protect
cynomolgu
macaqu
marv
infect
administ
late
hr
follow
infect
appear
inhibit
viral
rna
polymeras
function
act
probabl
rna
chain
also
effect
treat
yellow
fever
viru
yfv
infect
hamster
model
even
treatment
initi
peak
viral
phase
studi
evalu
safeti
toler
pharmacokinet
properti
administ
via
intramuscular
inject
healthi
volunt
announc
biocryst
pharmaceut
durham
nc
usa
middl
decemb
brincidofovir
bcv
fig
oral
nucleotid
analogu
vitro
vivo
antivir
activ
dsdna
virus
effect
includ
hexadecyloxypropyl
prodrug
cidofovir
fig
acycl
nucleosid
approv
fad
treatment
cytomegaloviru
cmv
infect
develop
chimerix
durham
nc
usa
sever
key
advantag
compar
parent
compound
improv
oral
bioavail
rapid
transport
across
cell
membran
lead
higher
intracellular
concentr
activ
speci
greater
potenc
elimin
brincidofovir
actual
receiv
fast
track
design
fda
treatment
cmv
adenoviru
smallpox
infect
quit
surprisingli
investig
antivir
brincidofovir
consid
antivir
expert
specif
treatment
dna
viral
diseas
show
vitro
activ
ebov
thu
potenti
use
patient
evd
addit
assess
anim
model
studi
conduct
center
diseas
control
prevent
cdc
nation
institut
health
nih
chimerix
announc
octob
emerg
investig
new
drug
applic
eind
brincidofovir
author
us
food
drug
administr
fda
evd
probabl
interfer
certain
enzym
nucleo
ide
metabol
exact
mechan
ebov
inhibit
remain
clarifi
class
imidazol
nucleosid
nucleotid
analogu
bear
either
nitril
ester
group
imidazol
compound
gener
structur
fig
report
inhibit
replic
lassa
viru
sever
acut
respiratori
syndrom
sar
coronaviru
ebov
vitro
employ
acycl
nucleotid
analogu
fig
exampl
show
suggest
report
activ
may
link
cytotox
valu
compound
ebov
rang
mechan
action
analogu
remain
favipiravir
fig
antivir
agent
activ
mani
rna
virus
picornavirus
discov
develop
toyama
chemic
co
toyama
japan
viru
approv
japan
influenza
treatment
brand
name
avigan
favipiravir
current
undergo
phase
iii
clinic
trial
unit
state
vivo
efficaci
recent
confirm
mous
model
ebov
postexposur
initi
administr
complet
prevent
lethal
vitro
effici
convert
cellular
enzym
ribofuranosyl
rtp
fig
activ
speci
suggest
select
inhibit
influenza
viru
rna
rtp
recogn
influenza
viru
polymeras
effici
substrat
incorpor
rna
guanosin
adenosin
analogu
two
consecut
incorpor
shown
prevent
primer
baranovich
et
report
lethal
mutagenesi
key
antivir
mechan
also
explain
antivir
activ
favipiravir
given
sever
ebola
patient
uniqu
mechan
action
current
repres
promis
candid
evd
treatment
section
includ
structur
divers
compound
report
inhibit
cell
entri
filovirus
sever
agent
discuss
repurpos
drug
number
compound
distinct
structur
featur
report
potenti
entri
inhibitor
ebov
entri
requir
function
cholesterol
transport
protein
shown
cell
defect
function
bind
viral
gp
resist
infect
ebov
marv
inhibitor
deriv
benzylpiperazin
adamantan
diamid
eg
compound
fig
describ
interfer
gp
bind
sinc
process
essenti
ebov
infect
seem
repres
good
target
potenti
antivir
therapi
wolf
et
report
discoveri
promis
antivir
agent
fig
activ
impress
number
envelop
virus
effect
influenza
flavivirus
hiv
effect
infect
nonenvelop
virus
intercal
viral
membran
prevent
fusion
host
cell
overcom
toxic
effect
due
repair
cellular
lipid
biosynthesi
rhodanin
deriv
suggest
inhibit
viral
entri
step
viru
bind
fusion
molecular
target
molecular
mechan
remain
elus
later
vigant
et
identifi
unsatur
fatti
acid
chain
viral
membran
phospholipid
major
target
antivir
activ
membran
bilay
gener
singlet
oxygen
subsequ
lipid
oxid
result
chang
biophys
properti
viral
membran
disrupt
viru
abil
undergo
fusion
furthermor
elucid
mode
action
subsequ
relationship
sar
optim
led
new
class
exampl
compound
fig
photosensit
increas
potenc
quantum
yield
absorpt
spectra
seri
benzodiazepin
compound
repres
deriv
fig
report
potenti
entri
inhibitor
compound
valid
inhibitor
ebov
marv
assay
inhibitori
concentr
respect
hypothes
bind
hydrophob
pocket
ebov
interfac
consequ
inhibit
ebov
infect
cell
pyridinyl
imidazol
inhibitor
map
kinas
exampl
compound
fig
found
impair
viral
entri
reduc
cytokin
induct
reduc
viral
replic
human
cell
primari
human
monocyt
deriv
dendrit
cell
mddc
kinas
well
phosphatas
inhibitor
may
repres
new
lead
uniqu
strategi
antifiloviru
therapeut
develop
compound
report
activ
recent
review
yermolina
et
report
novel
group
select
inhibitor
filovir
entri
select
inhibit
ebov
marv
gp
mediat
infect
human
cell
extens
sar
studi
led
identif
lead
compound
fig
select
inhibitor
filovir
entri
also
sever
natur
product
abl
impair
microfila
function
includ
latrunculin
fig
cytochalasin
shown
potent
inhibitor
ebov
viru
gp
mediat
entri
novel
screen
ht
assay
small
molecul
led
identif
novel
compound
abl
block
cathepsin
l
catl
cleavag
viral
gp
deriv
ebov
hendra
nipah
virus
requir
entri
host
parent
compound
fig
deriv
fig
show
respect
cytotox
fulleren
sugar
ball
repres
new
class
biolog
activ
glycofulleren
found
effici
inhibit
lectin
cell
infect
sever
mannosyl
fulleren
sugar
ball
show
remark
ebov
thu
consid
promis
tool
interfer
ebov
entri
drug
repurpos
drug
reposit
potenti
applic
known
compound
new
indic
therefor
systemat
screen
drug
could
rapidli
becom
avail
new
indic
emerg
includ
ebov
chlorpromazin
trademarket
thorazin
largactil
megaphen
fig
known
psychotrop
drug
approv
fda
report
potenti
inhibitor
ebov
entri
possibl
inhibit
select
estrogen
receptor
modul
serm
includ
clomifen
trademark
androx
clomid
omifin
fig
toremifen
brand
name
fareston
identifi
potent
inhibitor
ebov
infect
vitro
screen
readili
avail
approv
author
suggest
mode
action
serm
involv
classic
pathway
associ
estrogen
receptor
instead
interfer
late
step
viral
antiarrhytm
agent
amiodaron
channel
inhibitor
fig
dronedaron
exampl
drug
could
found
inhibit
filoviru
entri
concentr
routin
reach
human
serum
antiarrhythm
exampl
show
drug
repurpos
may
viabl
approach
identif
potent
therapeut
function
genet
inc
gaithersburg
md
usa
report
seri
polyaromat
compound
activ
distinct
virus
inhibitor
filoviru
infect
design
fig
identifi
via
ht
compound
librari
nation
cancer
institut
nci
exhibit
antivir
activ
ebov
sudv
well
multipl
strain
although
mechan
action
unknown
shown
murin
model
ebov
infect
reduc
viremia
viral
burden
organ
tissu
could
applic
prophylact
therapeut
treatment
fig
diazachrysen
daac
base
analogu
discov
ht
potent
inhibitor
lethal
vhf
pathogen
includ
ebov
rift
valley
dengu
fever
virus
protect
mice
otherwis
lethal
ebov
infect
prophylact
therapeut
set
also
reveal
potenti
inhibitori
activ
viral
pathogen
includ
hiv
precis
mode
action
remain
natur
antivir
activ
analogu
may
suggest
target
conserv
host
convent
antivir
design
target
viral
encod
proteinsenzym
mechan
disadvantag
convent
antivir
often
toxic
host
develop
resist
viral
strain
render
rel
quickli
ineffect
prevent
resist
problem
combin
therapi
use
cocktail
drug
variou
mode
action
success
introduc
approv
therapeut
repres
anoth
import
approach
combat
establish
well
emerg
viral
approach
base
target
host
deni
viral
pathogen
abil
caus
diseas
structur
modif
studi
promis
inhibitor
compound
fig
identifi
highli
efficaci
ebov
marv
inhibitor
valu
respect
littl
associ
cellular
recent
inhibitor
ebov
structur
origin
given
report
might
target
host
protein
play
essenti
role
viral
life
cycl
interact
filoviru
matrix
protein
key
vp
drive
bud
facilit
viral
addit
demonstr
inhibit
multipl
emerg
virus
eg
ebov
cowpox
pathogen
eg
hbv
hcv
hiv
chaotic
name
use
whole
famili
compound
fig
mention
prefer
compound
list
retinoid
thiosemicarbazon
deriv
retinazon
rtz
fig
describ
antivir
agent
activ
hiv
hcv
vzv
cmv
rtz
found
potent
suppressor
hcv
rna
replicon
later
rtz
also
report
potent
efficaci
inhibitor
ebov
valu
sinc
activ
may
link
cytotox
iminosugar
dnj
deriv
glucos
mimic
serv
glucosidas
inhibitor
shown
exhibit
antivir
effect
number
envelop
virus
dnj
deriv
fig
shown
exhibit
vitro
vivo
inhibitori
activ
endoplasm
reticulum
er
demonstr
vivo
efficaci
lethal
dengu
viru
infect
extens
sar
studi
deriv
lead
identif
novel
iminosugar
exampl
compound
fig
significantli
reduc
mortal
marv
ebov
infect
signific
surviv
rate
exampl
observ
mgkg
murin
model
ebov
infect
treatment
initi
hr
post
viru
challeng
multifunct
anoth
attract
therapeut
target
play
critic
role
ebola
viral
replic
knowledg
structur
domain
term
iid
provid
opportun
antivir
use
silico
screen
method
brown
et
identifi
sever
compound
exampl
repres
compound
fig
capabl
bind
iid
high
affin
specif
compound
also
shown
inhibit
ebov
recent
ht
subset
drug
report
also
antimalari
amodiaquin
chloroquin
activ
vitro
vivo
ebov
singl
digit
micromolar
mechan
action
unclear
later
compound
dock
favor
suggest
may
target
vp
furthermor
chloroquin
shown
block
ebov
viru
like
particl
entri
select
index
si
screen
ebov
inhibitor
lead
identif
nsc
fig
compound
act
scaveng
reactiv
oxygen
speci
ro
upregul
oxid
stress
induc
gene
ro
contribut
pathogenesi
wide
array
diseas
includ
viral
infect
nsc
shown
inhibit
ebov
marv
rift
valley
fever
viru
lassa
viru
venezuelan
equin
enceph
viru
assay
vivo
protect
mice
follow
challeng
ebov
marv
bud
broad
rang
rna
virus
facilit
subvers
host
protein
eg
viral
ppxi
late
bud
domain
express
within
matrix
protein
virus
silico
design
subsequ
sar
studi
result
identif
lead
compound
fig
abil
inhibit
critic
addit
compound
exhibit
antibud
activ
ebov
rna
virus
thu
serv
lead
structur
develop
novel
antivir
ptap
type
l
domain
anoth
domain
util
number
rna
virus
eg
junin
viru
ebov
bud
process
thu
recent
identifi
ptap
inhibitor
compound
structur
analogu
fig
potenti
act
potent
antivir
drug
rna
virus
present
good
target
rapidli
advanc
field
antisens
strategi
usual
util
dna
oligonucleotid
inhibit
protein
product
bind
specif
site
mrna
essenti
translat
mediat
catalyt
degrad
target
rna
oligonucleotid
known
rna
sirna
also
mediat
catalyt
degrad
complementari
mrna
thu
antisens
rnai
strategi
find
therapeut
applic
treatment
highli
pathogen
rna
viral
infect
phosphorodiamid
morpholino
oligom
pmo
design
inhibit
translat
ebov
l
pmo
report
show
reduc
viral
titer
cell
cultur
provid
complet
protect
rodent
administ
postexposur
therapeut
regimen
pmo
also
protect
rhesu
macaqu
prophylact
sarepta
therapeut
cambridg
usa
formerli
avi
biopharma
develop
pmo
contain
five
posit
charg
linkag
pmoplu
fig
significantli
improv
stabil
efficaci
specif
deliveri
safeti
antisens
complex
chemic
evolut
antisens
molecul
led
discoveri
two
new
therapeut
agent
target
transcript
ebov
target
np
transcript
protein
inhibitor
type
interferon
respons
also
form
homodim
bind
np
thu
may
play
import
role
switch
viral
replic
transcript
function
critic
viral
life
cycl
inhibit
may
lead
effici
host
respons
viral
infect
recent
heald
et
evalu
safeti
pharmacokinet
properti
two
combin
drug
combin
combin
evalu
postexposur
prophylaxi
ebov
marv
respect
addit
studi
nonhuman
primat
human
progress
estim
protect
human
rnai
may
also
prove
effect
druggabl
therapi
filoviru
sirna
target
ebov
rna
polymeras
formul
stabl
nucleic
acid
lipid
particl
snalp
complet
protect
guinea
pig
administ
shortli
ebov
sirna
experi
primat
lethal
ebola
viru
infect
show
full
postexposur
protect
rhesu
monkey
macaqu
although
observ
advers
event
fever
subject
phase
studi
caus
sirna
develop
tekmira
pharmaceut
burnabi
canada
place
partial
clinic
hold
fda
still
author
use
treat
patient
confirm
suspect
ebov
infect
expand
access
protocol
bdbv
bundibugyo
ebolaviru
cmv
cytomegalovirusebov
zair
ebolaviru
ebolaehf
ebola
hemorrhag
feverevd
ebola
viru
diseaseht
screeningmarv
marburgviru
pmo
phosphorodiamid
morpholino
oligomerrafi
rigid
amphipath
fusion
inhibitorrestv
reston
ebolaviru
sah
relationshipsirna
rnasnalp
stabl
nucleic
acid
lipid
particlesudv
sudan
ebolaviru
tafv
forest
ebolaviru
vhf
viral
hemorrhag
fevervp
viral
protein
